Grant: Project Grant
McMaster University
$845,326.00
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Randomized Control Trial
FY 2023-24
Summary
There are increasing number of people receiving a new type of blood thinner called direct oral anticoagulants (DOACs) to prevent a stroke if they have an irregular heartbeat (referred to as atrial fibrillation [AF]). Most people may need to stop these drugs before a surgery/procedure depending on the risk for bleeding in a surgery. Knowing when to stop and restart these drugs is not known, and it is important to know, so that the patients' risk of developing bleeding or a stroke is minimized. For patients with AF requiring a complicated surgery, the risk for bleeding is high. This study will compare and show the safety of two different recommended strategies, PAUSE or ASRA, for stopping and starting DOACs (dabigatran, rivaroxaban or apixaban) before and after surgery in those high risk procedures by comparing the level of residual DOAC at the time of surgery . Both approaches are being commonly used. Patients enrolling in one or another approach will be randomly assigned with equal number in both groups.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
490097
Name
Douketis James D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials
Projecttitle
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Randomized Control Trial
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$845,326
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Arterial Thromboembolism; Asra Guidelines; Atrial Fibrillation; Blood Thinners; Direct Oral Anticoagulant; Doac; Elective Surgery; Major Bleed; Perioperative Doac Management; Perioperative Management
Abstract
There are increasing number of people receiving a new type of blood thinner called direct oral anticoagulants (DOACs) to prevent a stroke if they have an irregular heartbeat (referred to as atrial fibrillation [AF]). Most people may need to stop these drugs before a surgery/procedure depending on the risk for bleeding in a surgery. Knowing when to stop and restart these drugs is not known, and it is important to know, so that the patients' risk of developing bleeding or a stroke is minimized. For patients with AF requiring a complicated surgery, the risk for bleeding is high. This study will compare and show the safety of two different recommended strategies, PAUSE or ASRA, for stopping and starting DOACs (dabigatran, rivaroxaban or apixaban) before and after surgery in those high risk procedures by comparing the level of residual DOAC at the time of surgery . Both approaches are being commonly used. Patients enrolling in one or another approach will be randomly assigned with equal number in both groups.
Competitiondate
202309
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Douketis, James D
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $845,326~ $0~
